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ABSTRACT 
 
Aim: Clotrimazole (CTZ) is a broad spectrum anti-fungal drug which faces inability to retain over 
skin for longer duration and faces systemic side effects. The rationale behind present research 
effort was to attain sustained release of drug by lipid nanocarriers, enhance absorption by 
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prolonged retention of gel and improve the patient compliance by reducing the dosing frequency.  
Study Design: CTZ solid lipid nanoparticles (SLN) were prepared by solvent emulsification 
method and loaded into sodium hyaluronate (Na-Hy) gel.  
Methodology: CTZ-SLN were formulated and characterized, loaded into sodium hyaluronate (Na-
Hy) gel.. Later assessed for in vitro release, in vitro bioadhesion, and in vitro antifungal activity. 
Results: FT-IR and DSC studies revealed no chemical changes or interaction occurred. Optimized 
CTZ-SLN exhibited the particle size 248 ± 1.31 nm, zeta potential 16.2 mv, entrapment efficiency 
was 80.7±0.7%, and drug loading 21.8±0.5%. The optimized CTZ SLN loaded Na-Hy gel 
demonstrated prolonged drug release (upto 24 h) than the conventional dosage form Canesten 
1%, which got exhausted within 4 h. CTZ-SLN Na-Hy gel exhibited enhanced in vitro bioadhesion 
and in vitro antifungal action compared to conventional dosage form Canesten ointment against          
a) Candida albicans b) Saccharomyces cerevisiae c) Candida glabrata d) Candida tropicalis.  
Conclusion: Aforementioned outcomes make the promising applicability of formulated CTZ-SLN 
Na-Hy gel as a potential drug delivery system for local therapy of vaginal candidiasis and other 
similar infections. 
 
 
Keywords: Clotrimazole; solid lipid nanoparticles; sodium hyaluronate gel; vaginal candidiasis. 
 
ABBREVIATIONS 
 
CTZ :  Clotrimazole 
SLN :  Solid lipid nanoparticles  
Na-Hy :  Sodium hyaluronate 
 
1. INTRODUCTION 
 
Vaginitis is characterized by irritation and 
inflammation in the vagina, due to the infection in 
the vulva. Vaginal candidiasis is most prevalent 
and women of all ages prone to it. Undeniably, 
75% of all women are prone to this infection once 
in their lifetime and 40-45% are prone to multiple 
episodes in their lifetime [1,2]. Denial or delay of 
treatment may lead to several complications, 
pronouncedly in pregnant women. Among                     
the vulvovaginitis cases, infectious vaginitis                    
was reported in about 90% which may be    
caused by the Candida species or bacterial 
species [3].  
 
Candida is one of the commensal flora found in 
the gut, mouth, and genital tracts. They 
proliferate if alterations in their environment 
occur. Immuno suppression, antibiotics usage, 
pregnancy, menstrual cycle, diabetes mellitus 
may cause alteration in the environment and 
support the yeast proliferation [4]. Along with the 
infection, termination of useful microbes from the 
vaginal flora may occur. Lactic acid generation 
occurs in the genital tract which is the major 
metabolite from lactobacillus. And lactic acid has 
vital role in maintenance of normal vaginal pH of 
3.8-4.4. Elevation of pH to 5.5-6.8 may cause 
proliferation of pathogeneic micro-organisms. 
Extreme acidic environment obstructs the 
proliferation of Lactobacillus and cause vaginal 
candidiasis infections [5]. 
Most of the vaginal candidiasis cases arises due 
to Candida albicans species but recurrent or 
chronic form of diseases are caused by the non-
albicans species [6-8]. Non-albicans species 
have low reactivity to azole antifungal [9]. 
Researchers consider that alarming rate of 
vaginal infections is caused by non-albicans, (C. 
glabrata, C. tropicalis and C. dubliniensis) which 
was witnessed in the recent times [10,11]. It has 
been reported that azole resistance was attained 
by the Candida species; specifically C. glabrata 
isolates and even long term administration of 
anti-fungal drugs may lead to recurrent vaginitis 
[12,13]. Resistance development made the 
researchers interest towards the exploration of 
an effective drug moiety [14]. Multi-factorial 
pathogenesis and increased resistant strains of 
Candida hinder the exisiting therapies [15,16]. 
 
Clotrimazole (CTZ) is classified under class of 
Imidazole derivatives. It is effective against 
several species i.e., Isolates of dermatophytes, 
pathogenic yeasts, and filamentous and 
dimorphic fungi, as well as some gram-positive 
bacteria. O-Prasertsawat P et al. [17] have 
reported by their comparative study that CTZ can 
be considered as an alternate drug for the 
vulvovaginal candidiasis therapy. There wasn’t 
any significant differences in the clinical and 
overall cure rates when compared with 
Itraconazole and Fluconazole. CTZ (Canesten 
1%) can be applicable for the first-line therapy for 
vulvovaginal candidiasis [18]. These evidences 
suggest that CTZ can be considered for the 
treatment of vulvovaginal candidiasis. It is 
indicated topical treatments i.e 1% cream, 
applied twice daily & 100 mg, 200 mg or 500 mg 
pessaries [19,20]. The Long term oral 
administration of the CTZ (100 mg/kg) for few 
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weeks resulted in gastrointestinal and hepatic 
adverse effects and drug interactions i.e 
interaction with hepatic microsomal enzymes 
with subsequent interference with its own 
metabolism. Its low bioavailability and its 
log P value (3.5) indicate that it is highly 
hydrophobic in nature, and pKa (6.7) permits its 
transdermal application. The topical 
administration minimizes the systemic side 
effects and toxicities and it is beneficial due to 
direct delivery and targetability at site of action  
despite low bioavailability hinders the topical 
delivery [21,22]. However, currently available 
topical formulations are not capable of retaining 
the drug on the skin for longer duration so 
rationalization and development of formulations 
with longer retention time are essential [23]. 
 
Several researchers were successful in 
overcoming the aforementioned issues by 
exploiting the solid lipid nanoparticles (SLN) for 
topical administration. Utilizing the SLN drug 
delivery system, fungal burden was effectively 
diminished and exhibited significant therapeutic 
efficacy when compared with the commercially 
available formulations [24-27]. These evidences 
illustrate the success rate and potential of SLN 
as drug delivery system for topical administration 
of CTZ. Stratum corneum is the primary site of 
action for the CTZ where the pathogens reside 
mainly. The range of Minimum inhibitory 
concentration (MIC) of CTZ is between 0.001-
0.01 µg/ml and fungal inhibitory concentration is 
between 0.003–0.006 µg/ml. To achieve effective 
therapeutic action drug concentration should be 
above the MIC at the site of action. So, in this 
aspect we adopted SLN to achieve the controlled 
drug delivery to maintain the drug concentration 
in deeper layers of the skin [27].  
 
Vaginal Candidiasis is associated with several 
symptoms like heavy white curd-like vaginal 
discharge and dryness [28]. To retain the CTZ-
SLN at the site of action another medium is 
necessary for the bypassing the aforementioned 
problems. This can be overcome by the concept 
of ‘bio-adhesion’ because our target is 
“underlying tissue”. So, a suitable medium is 
necessary for the CTZ-SLN to be occluded in the 
aqueous environment and protect from the 
vaginal discharge which may increase the 
availability of the drug at the target underlying 
tissue [29]. 
 
In this context, Hyaluronic acid (HA) gel was 
employed in our study as it is characterized by 
high viscous and adhesion features which may 
lead to prolonged presence of drug at the site of 
application [30,31]. HA is a linear chained 
polysaccharide classified under the family of 
glycosaminoglycans which are principal 
constituents of the extra cellular matrix. In 
physiological pH, it exhibits a polyanionic 
structure that gives good hydro-coordinating 
features facilitating the water-retention [32]. 
Vaginal dryness condition in the vaginal 
candidiasis can be avoided by the water 
retention property of HA [33]. So, loading of CTZ-
SLN in HA gel tends to achieve sustained 
release of drug from the lipid shell and vaginal 
discharge can be avoided. So, the present work 
focused on developing CTZ-SLN loaded HA gel 
for the vaginal candidiasis treatment.  
 
2. MATERIALS AND METHODS 
 
2.1 Materials  
 
Palmitic acid and Ethanol- HPLC grade were 
purchased from SD-Fine chemicals limited, 
Mumbai, India. Clotrimazole HCl and Poloxamer 
188 (F68) were purchased from Sigma-Aldrich, 
Bangalore, India. Sabouraud Dextrose Agar was 
purchased from Himedia chemicals Ltd, Mumbai, 
India. Sodium hyaluronate with a molecular 
weight of approximately 1300 kDa was a gift 
sample from Kumar organic products Ltd., 
Bangalore, India. All other chemicals and 
reagents used were of analytical grade. Millipore 
water was utilized for all the studies. The 
organisms a) Candida albicans b) 
Saccharomyces cerevisiae c) Candida glabrata 
d) Candida tropicalis was obtained from Institute 
of Microbial Technology (IMTECH), Chandigarh, 
India.  
 
2.2 Pre-formulation Studies  
 
2.2.1 Drug-lipid interaction study by 
differential scanning calorimetry (DSC) 
analysis 
 
The interaction between CTZ and palmitic acid 
was determined the melting points using the 
DSC. Thermograms were recorded for CTZ, 
palmitic acid, physical mixture and CTZ-SLN. 
High purity indium metal was employed as 
standard for instrumental calibration. In nitrogen 
atmosphere, with a heating rate of 10°C/min, 
dynamic scans were carried out at temperature 
range 10-300°C. 
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2.3 Preparation of CTZ-SLN 
 
CTZ-SLN were prepared by solvent diffusion 
technique with slight modifications [34]. Palmitic 
acid and CTZ were dissolved completely in 
ethanol in a water bath at 70°C. The obtained 
organic solution was immediately dispersed into 
aqueous phase containing Poloxamer 188 (F68) 
under continuous mechanical agitation at 400 
rpm in a water bath at 70°C for 5 minutes. The 
resultant pre-emulsion (melted lipid droplet) was 
transferred into an ice bath to solidify the lipid 
droplets and then brought to room temperature 
till SLN dispersion was formed. The SLN 
dispersion was dialyzed in distilled water for 12 
hours to remove water-soluble impurities 
(organic solvents and nonadsorbed surfactants) 
and subsequently centrifuged (7000 rpm, 5 
minutes) to remove unentrapped CTZ and larger 
lipid particles. The final SLN dispersant was 
lyophilized. 
 
2.4 Drug Loading and Encapsulation 
Efficiency 
 
SLNs (100 mg) were extracted with 5 mL of 
ethanol, diluted with pH 4.5 citrate-phos                   
phate buffer, filtered and analyzed for                       
drug content after suitable dilution, at 263 nm 
[35]. 
 
2.5 In vitro Drug Release Studies 
 
Release studies were carried out on prepared 
formulations in triplicate, employing a basket type 
dissolution tester-USP XXII (TDT-08L, 
Electrolab, India) using 600 mL of pH 4.5 citrate 
phosphate buffer as dissolution medium at 100 
rpm at 37 ± 0.5°C to mimic the vaginal conditions 
[36-38]. Five ml of the sample was withdrawn at 
different intervals and analyzed by the UV 
method at 263 nm [35]. 
 
2.6 Determination of Particle Size, Zeta 
Potential and Morphology 
 
The particle size, zeta potential, and 
polydispersity index were determined by 
zetasizer 3000HAS (Malvern Instruments Ltd, 
Malvern, UK). Before measurement the samples 
were suspended in deionized water (1 mg/ml). All 
measurements were carried out at 25°C and 
performed in triplicate. The morphology of CTZ-
SLNs was determined by scanning electron 
microscopy (SEM, JEM-200 CX, JEOL, Tokyo, 
Japan) [39]. 
2.7 Determination of Drug Entrapment 
Efficiency and Drug Loading  
 
The quantity of CTZ in SLN was determined by 
HPLC. About 10 mg prepared SLN was 
dissolved in 10 ml of ethanol and then 
centrifuged by a Sigma-3k 30 Centrifuges 
(Sigma-Aldrich, Seelze, Germany) with 14 000 
rpm for 10 min at the temperature of 37°C. 
Further, extraction by ethanol and filteration 
using 0.45 mm filter was carried out. The drug 
content in the supernatant was measured by 
HPLC method using an mobile phase delivery 
pump (LC-20 AD; Shimadzu, Japan) of flow rate 
1.0 ml min−1, a photodiode array detector 
(SPDM20A; Shimadzu, Japan) set at 222 nm, a 
20 µL loop (Rheodyne) and Phenomenex Gemini 
C18 (250 mm × 4.6 mm) was used. The mobile 
phase consisted of ethanol and 25 mM of 
phosphate buffer (pH 4.0) in 80:20 ratio [40]. The 
encapsulation efficiency and drug loading were 
calculated by the following formulae.  
 
Entrapment eficiency%
=
Weight of drug in SLN
Weight of the drug fed initially
× 100 
 
Drug loading %
=
Weight of drug in SLN
Weight of SLN recovered
× 100 
 
2.8 Formulation of CTZ-SLN Loaded Na-
Hy Gel 
 
Na-Hy gels were prepared by dissolving Sodium 
hyaluronate with a molecular weight of 
approximately 1300 kDa [41,42] (2.28% w/v) in 
HEPES/NaCl buffer (10/115 mM, pH 7.4). CTZ-
SLNs were dispersed in the gel. Then gels were 
triturated using a magnetic stirrer, maintained at 
room temperature for 1 h and stored at 4°C for 
12h prior to administration or analysis [43]. 
 
2.9 In vitro Release Studies 
 
The in vitro drug release studies were carried out 
using Franz diffusion cell (Perme Gear Inc., 
Bethlehem, PA) with donor chamber and water 
jacketed receptor chamber (20 ml) maintained at 
37°C [44]. Commercial semi-permeable 
cellophane membrane (Fischer Scientific Co., 
London, England; pore size 0.45 µm) was 
utilized as permeation barrier which was rinsed 
overnight in Simulated Vaginal Fluid (SVF) 
before the study. 1 gm of gel was applied 
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carefully on permeation membrane; which was 
lodged between the donor and receptor 
compartments. Receptor compartment was 
maintained with 20 ml SVF, while donor 
compartment was vacant and uncovered. The 
conditions of receptor compartment were 
maintained at 37.5°C with continuous stirring at 
rate 25 rpm using a magnetic stirrer. At regular 
time intervals, 5 ml - Aliquots were withdrawn 
from receptor compartment and equivalent 
amount of fresh media (37±5°C) was replaced to 
maintain the sink conditions. After withdrawal   
the samples were analyzed by UV-spectrometer 
at 263 nm. The study was carried out in triplicate.  
 
2.10 Determination of pH 
 
The pH of prepared Na-Hy 2% (w/w) gel was 
detected using a digital pH meter (Mettler Toledo 
MP 220, Greifensee, Switzerland) at 25 °C in 
triplicate. 
 
2.11 Determination of Viscosity  
 
Viscosity of Placebo Na-Hy gel and developed 
CTZ-SLN loaded Na-Hy based gel was 
evaluated using Brookfield viscometer (DV-II, LV 
model, Brookfield, USA). The viscosity was 
determined (n=3) at three different conditions 
(4°C, 25°C and 37°C) at different rotational 
speeds from 0.5-20 rpm with a torque of near to 
100%. The samples were equilibrated for 10 min 
prior to the analysis [45]. 
 
2.12 Determination of Spreadability 
 
Wide spreadability is one of the requisite for a gel 
preparation to meet the ideal qualities. It is 
evaluated by the extent of area to which gel 
immediately spreads at site of application. The 
spreadability was determined by applying 0.5 g 
gel within a pre-marked circular area of 1 cm 
diameter on a glass plate with specifications of 5 
mm thickness and 15 cm2 area. And another 
glass plate with equal dimensions was placed    
on it; ensure that entrapment of the air       
bubbles avoided between two slides. Standard 
weight of 500 g was placed on the upper        
glass plate for 5 min to spread the gel uniformly. 
Higher the area of the gel spread over the      
plate is an indicator of efficient spreadability   
[46]. 
 
2.13 In vitro Bioadhesion Studies 
 
In vitro bioadhesive potential of CTZ loaded Na-
Hy gel, CTZ-SLN loaded Na-Hy gel was 
evaluated and compared with placebo                         
Na-Hy gel, In brief, an agar plate (1%, w/w) was 
prepared in pH 4.5 citrate phosphate buffer (pH = 
4.5) and sample (50 mg) was applied at central 
location and left for 5 min. Then, plate was fixed 
with USP disintegration test apparatus and made 
upward downward movements in SVF (pH 4.5) at 
37°C. The movement of instrument arm was 
made in such that the sample on the agar                      
plate was submerged into buffer at the                            
low position and was taken out of solution at the 
high position. By visual observation, the 
residence time of samples on plate was 
determined [47].  
 
2.14 In vitro Antifungal Studies 
 
Antifungal activity was evaluated by the cup-plate 
method using Sabouraud Dextrose Agar plates 
inoculated with different fungal species                     
a) Candida albicans b) Saccharomyces 
cerevisiae c) Candida glabrata d) Candida 
tropicalis. A volume of 20 mL of sterilized agar 
media was dispersed into a sterilized Petri dish 
and allowed to solidify. Each Petri dish was 
divided into three sectors, and a bore (6 mm) 
was made in each sector using a sterile cork 
borer. Each bore in a different sector was loaded 
with a placebo polymer (negative control), 
Clotrimazole pure drug (positive control) and 
CTZ-SLN loaded gel. Petri dishes were 
incubated at the temperature of 37 ± 0.5°C for 24 
h to allow the growth of microorganisms. The 
zone of inhibition produced by the CTZ – SLN 
loaded Na-Hy gel towards the organism was 
measured (mm). 
 
3. RESULTS AND DISCUSSION 
 
3.1 Drug-Lipid Interaction Study by 
Differential Scanning Calorimetry 
(DSC) Analysis 
 
DSC thermogram of CTZ, Palmitic acid, physical 
mixture (drug, palmitic acid), and CTZ loaded 
SLNs are presented in (Fig 1). The DSC 
thermogram of CTZ and Palmitic acid exhibited a 
melting endotherm at 148°C and 63.1°C, 
respectively. No shift in the melting peaks                      
of physical mixture was observed as compared 
to melting endotherm of individual ingredient 
indicating the drug-lipid compatibility.                         
Melting endotherm for CTZ was not                            
formed in thermogram of final formulated                     
CTZ loaded SLNs (SLNs IV), indicating the drug 
was entirely occluded inside the lipid matrix of 
SLNs. 
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3.2 Drug Loading and Encapsulation 
Efficiency 
 
Encapsulation efficiency ranged from 67 to 80%. 
Generally the encapsulation efficiency and drug 
content increases with increasing amounts of 
polymers in the SLN. Formulation (SLNs IV) 
showed relatively higher encapsulation efficiency 
indicating high polymer concentration. It can be 
inferred from the results that there was a proper 
distribution of CTZ in the SLNs. During the 
encapsulation process, mechanical variables 
cause loss of the final product and hence 
process yield may not be 100%. Formulation 
(SLNs IV) showed maximum drug loading of 
21.8±0.5%. The results obtained are given in 
Table 1.  
 
3.3 In vitro Drug Release Studies 
 
The release profile of the drug from SLNs clearly 
indicates that the concentration of polymers 
slows the release of CTZ from SLNs. At the end 
of 12 h, in vitro drug release from formulation 
(SLNs IV) was found to be 98.8% in the vaginal 
environment, as shown in Fig. 2. The total 
cumulative quantity of the drug released                    
at the end of the 12 h dissolution test was below 
100%. This may be in part due to the relatively 
slow erosion of the matrix under these test 
conditions, with a resultant slow release of 
entrapped drug from the matrices undergoing 
testing. 
 
3.4  Physico-Chemical Characterization 
of CTZ-SLN 
 
SEM studies revealed that CTZ-SLN (SLNs IV) 
were almost uniform-sized; mono-dispersed 
spherical shaped. It was observed majority of 
SLN showed smooth surface morphology                
(Fig. 3). 
 
3.5 Particle Size Distribution 
 
The composition of optimized formulation (SLNs 
IV) showed particle size 248 ± 1.31 nm (Fig. 4), 
zeta potential -16.2 mv, drug loading 21.8 ± 
0.56% and entrapment efficiency 80.7% which 
were in good agreement with the predicted 
values particle size 247.44 nm and entrapment 
efficiency 82.02%. 
 
 
 
Fig. 1. DSC thermograms of CTZ, Palmitic acid, physical mixture and CTZ-SLN (SLNs IV) 
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Table 1. Evaluation parameters of CTZ SLNs 
 
Formulation 
(SLNs) 
CTZ 
(mg) 
Palmitic 
acid 
(mg) 
Poloxamer 
188 (F68) 
Ethanol 
(ml) 
Actual drug 
loading (%)a 
Encapsulation 
efficacy (%)a 
I 100 100 10 1 16.6±0.4 67.6±0.7 
II 100 200 20 2 18.2±0.9 72.3±0.4 
III 100 300 30 3 19.9±0.7 78.8±0.6 
IV 100 400 40 4 21.8±0.5 80.7±0.7 
V 100 500 50 5 19.6±0.4 79.9±0.7 
a Mean ± SD, n=3 
 
 
 
Fig. 2. Drug release profile of CTZ from SLNs (SLNs IV) (mean ± SD, n = 3) 
 
 
 
Fig. 3. SEM image of optimized CTZ-loaded 
SLN 
 
3.6 In vitro Release Studies 
 
In vitro drug release studies renders necessary 
information about the pretended release of the 
dosage form during in vivo conditions. The 
results of in vitro release studies exhibited 
prolonged drug release from the developed 
formulation. CTZ-SLN loaded Na-Hy gel had 
exhibited prolonged release upto 12h and it was 
devoid of any burst release. Prolonged release 
from lipid nanoparticles was due to slow erosion 
of SLN and accompanied by diffusion of drug into 
the external environment (Fig. 5). And the Na-Hy 
gels contribute the standby of the released drug 
at the site of action and this creates by-stander 
action of the drug. This creates scope for 
enhancing vaginal drug delivery and sustains the 
necessary drug concentration for the 
vulvovaginal candidiasis therapy. 
 
3.7 Determination of pH 
 
The pH of CTZ-SLN loaded Na-Hy gel was found 
to be 4.43 which is equivalent to vaginal pH.  
 
3.8 Determination of Viscosity  
 
Viscosity is an important rheological parameter 
involved in its usage. Higher viscosity hinders the 
instillation and lower viscosity cause drainage. 
So, an ideal viscosity gel is necessary to show 
effective delivery. There wasn’t any change or 
difference in the viscosity between placebo gel, 
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CTZ Na-Hy gel and CTZ-SLN Na-Hy gel. 
Presence of either CTZ-naïve or CTZ-SLN didn’t 
hinder the viscosity properties of the Na-Hy gel in 
different conditions (Table 2). 
 
3.9 Determination of Spreadability 
 
Spreadability is a vital feature of semisolid 
dosage forms which influence the ease of 
administration and patient compliance. Ideal gel 
will spread in a short duration which ultimately 
enhances the ease of application. Spreadability 
is calculated by the change in the diameter of 
earlier drawn circle (1 cm) by the application of 
weight. In case of Placebo gel exhibited 7.5 cm, 
CTZ Na-Hy gel of 7.2 cm and CTZ-SLN loaded 
Na-Hy gel exhibited 7.8 cm the overall elevation 
in diameter was reflects good spreadability of 
Na-Hy gel and no variation was observed in both 
samples. 
  
 
 
Fig. 4. Particle size distribution analysis report of optimized CTZ-SLN 
 
 
 
Fig. 5. In vitro release behavior assessment of CTZ loaded Na-Hy gel and CTZ-SLN loaded Na-
Hy gel at different pH 3.8 and 5.5 
 
Table 2. Determination of viscosity of placebo gel, CTZ Na-Hy gel and CTZ-SLN Na-Hy gel at 
different conditions 
 
Sample 4°C 25°C 37°C 
Placebo Na-Hy gel 88351 cps 786510 cps 782236 cps 
CTZ -SLN 89394 cps 784550 cps 791672 cps 
CTZ-SLN loaded Na-Hy gel 88716 cps 782400 cps 790149 cps 
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A B 
 
C D 
Fig. 6. In vitro anti fungal activity of Clotrimazole SLN loaded Na-Hy Gel (SLN-Gel) in 
comparison to Pure drug (CTZ) using different fungal strains: a) Candida albicans  
b) Saccharomyces cerevisiae c) Candida glabrata d) Candida tropicalis after 24 hrs. 
[Polymer- SLNs without drug] 
 
3.10 In vitro Bioadhesion Studies 
 
Bio-adhesion is the interfacial force held together 
between two materials (either two biological or 
synthetic and biological) for certain period of 
time. When an interaction occurs between any 
material (polymer/lipid) and epithelial surface is 
termed as bioadhesion. In the context of 
bioadhesive dosage forms, bioadhesion is 
adhesion occurring between soft tissues and 
polymers, either natural or synthetic. 
Determination of bioadhesion is crucial to confirm 
that adhesion caused by the developed Na-Hy 
gels is adequate for the prolonged retention at 
the site of administration. And high pressure 
should not injure the mucous membrane. The 
bioadhesive potential of CTZ-SLN loaded NA-Hy 
gel, CTZ loaded gel and placebo Na-Hy gel have 
exhibited 64±1.8 min, 64±1.2 min and 62±2.7 
min respectively (n = 3). Besides, the retention 
time of CTZ-SLN loaded Na-Hy gel was higher 
when compared with placebo gel.  Presence of 
Na-Hy gel provided sufficient retention and 
prolonged action was observed.   
 
3.11 In vitro Antifungal Studies 
 
An antifungal study with Sabouraud Dextrose 
Agar medium showed that the CTZ-SLN loaded 
gel was able to control (inhibit) the growth of 
different fungal species a) Candida albicans                     
b) Saccharomyces cerevisiae c) Candida 
glabrata d) Candida tropicalis for more than                         
24 h. The formulation (SLNs-gel) showed                        
an average zone of inhibition of 19.3 ± 0.5                       
mm, which was higher compared to the average 
zone of inhibition of pure Clotrimazole                        
(CTZ) i.e.,14.4 ± 0.4 mm. Also there was no 
significant effect produced by placebo polymer 
which implies that the polymer as such has no 
activity and no interference with the activity of the 
drug. 
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4. CONCLUSION 
 
CTZ loaded SLNs were developed using palmitic 
acid as lipid matrix, Pluronic F-68 as surfactant 
and ethanol as solvent using solvent injection 
method. Influencing parameters like surfactant 
concentration, amount of drug and volume of 
organic phase were selected for the optimization 
and carried out by Trial and error basis to 
develop a CTZ-SLN formulation with minimal 
particle size and higher entrapment efficiency. 
Optimized CTZ-SLN (SLNs IV) exhibited good 
particles which were in good agreement with the 
predicted values. CTZ-SLN has exhibited 
sustained release of drug. This kind of release is 
desirable when the dosage need to be reduced. 
The in vitro bio-adhesive potential was evaluated 
for CTZ-SLN loaded Na-Hy which was sufficient 
enough to avoid the drainage of the drug and 
exhibit bystander action at the site. MIC values of 
different fungal species a) Candida albicans b) 
Saccharomyces cerevisiae c) Candida glabrata 
d) Candida tropicalis have revealed good anti 
fungal activity of the CTZ-SLN loaded Na-Hy gel 
formulation. Earlier, extensive efforts and 
research has been focused on developing CTZ-
SLN [24-27] to diminish the fungal burden but 
delivery and patient compliance can be greatly 
improved by the Na-Hy delivery. 
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